Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony- stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation

Journal of Experimental Medicine

Volumn 190, Issue 3, 1999, Pages 355-366

  Van Elsas, Andrea ^a,b   Hurwitz, Arthur A ^a   Allison, James P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Autoimmunity; CTLA 4; Immunotherapy; Melanoma; Vitiligo

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ARTICLE; CANCER SURVIVAL; CYTOTOXIC T LYMPHOCYTE; FEMALE; HELPER CELL; HUMAN CELL; IMMUNOTHERAPY; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VITILIGO;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ANTIGENS, SURFACE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOIMMUNE DISEASES; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; FEMALE; GRAFT REJECTION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HAIR COLOR; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; LECTINS, C-TYPE; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PROTEINS; SKIN PIGMENTATION; T-LYMPHOCYTES, CYTOTOXIC; VITILIGO;

EID: 0033517152     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.190.3.355     Document Type: Article

References (44)

1. Boon, T., J.C. Cerottini, B. Van den Eynde, P. van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:337-365.
2. Rosenberg, S.A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today. 18:175-182.
3. Liu, G.Y., P.J. Fairchild, R.M. Smith, J.R. Prowle, D. Kioussis, and D.C. Wraith. 1995. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity. 3:407-415.
4. Poplonski, L.B., B. Vukusic, J. Pawling, S. Clapoff, J. Roder, N. Hozumi, and J. Whither. 1996. Tolerance is overcome in beef insulin-transgenic mice by activation of low-affinity autoreactive T cells. Eur. J. Immunol. 26:601-606.
5. Morgan, D.J., H.T.C. Kreuwel, S. Fleck, H.I. Levitsky, D.M. Pardoll, and L.A. Sherman. 1998. Activation of low avidity CTL for a self-epitope results in tumor rejection but not autoimmunity. J. Immunol. 160:643-651.
6. Overwijk, W.W., A. Tsung, K.E. Irvine, M.R. Parkhurst, T.J. Goletz, K. Tsung, M.W. Carroll, C. Liu, B. Moss, S.A. Rosenberg, et al. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self-reactive tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:277-286.
7. + T cells to cause immunopathology. J. Exp. Med. 187:763-774.
8. Allison, J.P. 1994. CD28-B7 interactions in T-cell activation. Curr. Opin. Immunol. 6:414-419.
9. Schwartz, R.H. 1990. A cell culture model for T lymphocyte clonal anergy. Science. 248:1349-1356.
10. + T cells by B7-transfected melanoma cells. Science. 259:368-370.
11. Chen, L., S. Ashe, W.A. Brady, I. Hellstrom, K.E. Hellstrom, J.A. Ledbetter, P. McGowan, and P.S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 71:1093-1102.
12. Thompson, C.B., and J.P. Allison. 1997. The emerging role of CTLA-4 as an immune attenuator. Immunity. 7:445-450.
13. Perez, V.L., L. Van Parijs, A. Biuckians, X.X. Zheng, T.B. Strom, and A.K. Abbas. 1997. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity. 6:411-417.
14. Leach, D., M. Krummel, and J.P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 271:1734-1736.
15. Hurwitz, A.A., A. van Elsas, D.R. Leach, J. Ziskin, J. Villasenor, T. Truong, and J.P. Allison. 1999. Manipulation of T cell activation to generate anti-tumor CTL. In Cytotoxic Cells: Basic Mechanisms and Medical Applications. M.V. Sitkovsky and P.A. Henkart, editors. Lippincott, Philadelphia. In press.
16. Kwon, E.D., A.A. Hurwitz, B.A. Foster, C. Madias, A.L. Feldhaus, N.M. Greenberg, M.B. Burg, and J.P. Allison. 1997. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Prof. Natl. Acad. Sci. USA. 94:8099-8103.
17. Hurwitz, A.A., T.F. Yu, D.R. Leach, and J.P. Allison. 1998. CTLA-4 blockade synergizes with tumor-derived GM-CSF for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA. 95:10067-10071.
18. Krummel, M.F., and J.P. Allison. 1995. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182:459-465.
19. Shen, Z., G. Reznikoff, G. Dranoff, and K.L. Rock. 1997. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol. 158: 2723-2730.
20. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R.C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete GM-CSF stimulates potent, specific, and long lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA. 90:3539-3543.
21. Hart, I.R. 1979. The selection of characterization of an invasive variant of the B16 melanoma. Am. J. Pathol. 97:587-600.
22. + T cells in the antitumor immune response. J. Exp. Med. 188:2357-2368.
23. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R.M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693-1702.
24. Huang, A.Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 264:961-965.
25. Banchereau, J., and R.M. Steinman. 1998. Dendritic cells and the control of immunity. Nature. 392:245-252.
26. Yang, Y., J. Zou, J. Mu, R. Wijesuriya, S. Ono, T. Walunas, J. Bluestone, H. Fujiwara, and T. Hamaoka. 1997. Enhanced induction of antitumor T-Cell responses by cytotoxic T lymphocyte associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res. 57:4036-4041.
27. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Prac. Natl. Acad. Sci. USA. 95:1178-1183.
28. Sotomoyer, E.M., I.M. Borrello, E. Tubb, J.P. Allison, and H.I. Levitsky. 1999. In vivo blockade of CTLA-4 enhances the priming of responsive T-cells, but fails to prevent the induction of tumor antigen-specific tolerance. Proc. Natl. Acad. Sci. USA. In press.
29. Levitsky, H.I., A. Lazenby, R.J. Hayashi, and D.M. Pardoll. 1994. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J. Exp. Med. 179:1215-1224.
30. Wu, T.C., A.Y.C. Huang, E.M. Jaffee, and D.M. Pardoll. 1995. A reassessment of the role of B7-1 expression in tumor rejection. J. Exp. Med. 182:1-7.
31. + T cell help. J. Exp. Med. 189:1157-1162.
32. Schoenberger, S.P., R.E. Toes, E.I. van der Voort, R. Offringa, and C.J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 393:480-483.
33. Bennett, S.R., F.R. Carbone, F. Karamalis, R.A. Flavell, J.F. Miller, and W.R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 393:478-480.
34. + T-helper and a T-killer cell. Nature. 393:474-478.
35. Richards, J.M., N. Mehta, K. Ramming, and P. Skosey. 1992. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J. Clin. Oncol. 10:1338-1343.
36. Rosenberg, S.A., and D.E. White. 1996. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol. 19:81-84.
37. Okamoto, T., R.F. Irie, S. Fujii, S.K. Huang, A.J. Nizze, D.L. Morton, and D.S. Hoon. 1998. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J. Invest. Dermatol. 111:1034-1039.
38. Ogg, G.S., P. Rod Dunbar, P. Romero, J.L. Chen, and V. Cerundolo. 1998. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J. Exp. Med. 188:1203-1208.
39. Kawakami, Y., S. Eliyahu, C.H. Delgado, P.F. Robbins, K. Sakaguch, E. Appella, J.R. Yannelli, G. Adema, T. Miki, and S.A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA. 91:6458-6462.
40. Bloom, M.B., D. Perry-Lalley, P.F. Robbins, Y. Li, M. el-Gamil, S.A. Rosenberg, and J.C. Yang. 1997. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185:453-459.
41. Naftzger, C., Y. Takechi, H. Kohda, I. Hara, S. Vijayasaradhi, and A.N. Houghton. 1996. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc. Natl. Acad. Sci. USA. 93:14809-14814.
42. Hara, I., Y. Takechi, and A.N. Houghton. 1995. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J. Exp. Med. 182:1609-1614.
43. + T lymphocytes. Proc. Natl. Acad. Sci. USA. 96:2982-2987.
44. Weber, L.W., W.B. Bowne, J.D. Wolchok, R. Srinivasan, J. Qin, Y. Moroi, R. Clynes, P. Song, J.J. Lewis, and A.N. Houghton. 1998. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J. Clin. Invest. 102:1258-1264.